Achaogen Awarded $24.7 Million Biodefense Contract By DTRA

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Achaogen, Inc., a developer of novel antibacterial compounds, has executed a four-year contract with the Defense Threat Reduction Agency (DTRA), an agency of the United States Department of Defense, worth up to $24.7 million dollars for the development of therapies to treat anthrax and other biothreat agents.

>>> Discuss This Story

Back to news